Long term differential consequences of miglustat therapy on intestinal disaccharidases.
about
A double-blind, randomized, placebo-controlled trial studying the effects of Saccharomyces boulardii on the gastrointestinal tolerability, safety, and pharmacokinetics of miglustat.Case study on the pathophysiology of Fabry disease: abnormalities of cellular membranes can be reversed by substrate reduction in vitro.The Pathobiochemistry of Gastrointestinal Symptoms in a Patient with Niemann-Pick Type C Disease.Structure-function analysis of human sucrase-isomaltase identifies key residues required for catalytic activity.
P2860
Long term differential consequences of miglustat therapy on intestinal disaccharidases.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Long term differential consequences of miglustat therapy on intestinal disaccharidases.
@en
Long term differential consequences of miglustat therapy on intestinal disaccharidases.
@nl
type
label
Long term differential consequences of miglustat therapy on intestinal disaccharidases.
@en
Long term differential consequences of miglustat therapy on intestinal disaccharidases.
@nl
prefLabel
Long term differential consequences of miglustat therapy on intestinal disaccharidases.
@en
Long term differential consequences of miglustat therapy on intestinal disaccharidases.
@nl
P2860
P1476
Long term differential consequences of miglustat therapy on intestinal disaccharidases
@en
P2093
Hassan Y Naim
P2860
P2888
P304
P356
10.1007/S10545-014-9725-4
P50
P577
2014-05-27T00:00:00Z
P5875
P6179
1044675470